Compare ConocoPhillips (COP) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Illumina, Inc. — how do they compare? ConocoPhillips trades at $125.8 (market cap $147.80B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: ConocoPhillips is far larger — about 5.1× Illumina, Inc.'s market cap, and ConocoPhillips pays a 2.73% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| COP | ILMN | |
|---|---|---|
Market Cap | $147.80B | $28.96B |
Sector | Energy | Health |
52-Week High | $133.80 | $205.10 |
52-Week Low | $85.66 | $91.00 |
Enterprise Value | $163.40B | $30.32B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $117.61, up 0.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $149.25. Recent Q2 2026 earnings beat expectations with EPS of $3.24 versus $2.90 estimated, driven by strong Permian Basin output and higher oil prices. The company reaffirmed its $7 billion free cash flow target by 2029 and completed a $1.7 billion asset sale ahead of schedule.
Outlook is positive due to robust operational performance and favorable oil market trends, but risks include commodity price volatility and CEO transition. The stock offers value with a P/E of 15.56 and a net income margin of 14.65%, supported by 74.51% analyst buy ratings.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
